Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from DarioHealth ( (DRIO) ) is now available.
On September 25, 2025, DarioHealth Corp. filed an Amended and Restated Certificate of Designation for its Series C-1 Preferred Stock to accelerate the mandatory conversion of shares into common stock or pre-funded warrants, ensuring holders receive accrued dividends. Additionally, the company announced a strategic review to maximize shareholder value, considering opportunities such as a sale or merger. Earlier, on September 22, 2025, DarioHealth announced a $17.5 million private placement of common stock to fund general corporate purposes.
The most recent analyst rating on (DRIO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on DarioHealth stock, see the DRIO Stock Forecast page.
Spark’s Take on DRIO Stock
According to Spark, TipRanks’ AI Analyst, DRIO is a Neutral.
DarioHealth’s overall stock score is primarily impacted by its financial challenges, including ongoing losses and high leverage. While technical indicators suggest a bearish trend, the company’s strategic initiatives and leadership changes provide some optimism for future growth.
To see Spark’s full report on DRIO stock, click here.
More about DarioHealth
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company that provides a user-centric, multi-chronic condition digital therapeutics platform. The platform offers personalized interventions for managing diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health, aiming to disrupt traditional healthcare approaches. DarioHealth serves health plans, self-insured employers, care providers, and consumers globally.
Average Trading Volume: 22,988
Technical Sentiment Signal: Sell
Current Market Cap: $23.01M
See more insights into DRIO stock on TipRanks’ Stock Analysis page.